Fen-Phen Malpractice Awards Denied By Texas High Court

Law360, Houston (December 13, 2013, 7:42 PM EST) -- The Texas Supreme Court refused Friday to reinstate a jury’s verdict that resulted in awards exceeding $10 million against a Houston attorney who allegedly overcharged clients in litigation against a Pfizer Inc. unit over the diet drug fen-phen.

The high court denied a petition for review pushed by a group of George Fleming’s former clients who were seeking to overturn a decision by the Fourteenth District Court of Appeals that testimony of a legal ethics expert in a test case “crossed the border of admissibility."...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.